LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Current Liabilities
All obligations due within one year.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 179.2% from a year ago
Total current liabilities stood at $10.91M at the end of Q1 FY2026, up 179.2% from a year earlier and up 46.5% from the prior quarter. Over 3 fiscal years it compounded at +151.3% a year.
Context
- Total current liabilities amounted to 2.8% of total assets at the end of Q1 FY2026, down 17.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +179.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.44M USD
- Year-over-year change
- -8.2%
- 3-year CAGR
- +151.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.44M | -8.2% |
| FY2024 | 2024-12-31 | 8.11M | +211.2% |
| FY2023 | 2023-12-31 | 2.61M | +455.7% |
| FY2022 | 2022-12-31 | 469K | — |
Total Current Liabilities vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total current liabilities of $10.91M is the lowest of the 10 companies compared; the peer median is $30.12M.
- Its year-over-year change of +179.2% is the 2nd highest of 10, against a peer median of +10.0%.
- Total current liabilities amounts to 2.8% of total assets for LBRX, versus a peer median of 4.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +156415.7% | +18.5% | 4.2% | |
| Sep 2026 | $332.22M | -6.8% | +30.2% | 18.5% | |
| Jun 2026 | $90.08M | -1.1% | -35.3% | 7.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $67.73M | +3.5% | +55.1% | 6.3% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $30.12M | +6.1% | +11.0% | 19.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M | +90.7% | +125.4% | 3.6% |
| Mar 2026 | $14.28M | +10.0% | +8.8% | 3.4% | |
| Mar 2026 | $13.12M | +80.7% | +26.8% | 4.7% | |
| Mar 2026 | $11.82M | +19.1% | +22.6% | 4.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M | +179.2% | +151.3% | 2.8% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $30.12M | +10.0% | +22.6% | 4.7% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.